報價延遲最少15分鐘:2026/02/28 16:49 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
23.39 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.83/-0.79
|
|
企業價值
2.25B
|
| 資產負債 |
|
每股賬面淨值
-0.83
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
673.00M
|
|
每股收益
4.25
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitatinggenetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated fromNorth America. |
